Application of progestational hormone in treatment of cytokine release syndrome

A technology of cytokines and syndromes, applied in the field of treatment of immune diseases and infectious diseases

Active Publication Date: 2021-04-16
SHENZHEN EVERGREEN THERAPEUTICS CO LTD
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

And when tocilizumab is ineffective for CAR-T patients, only a large amount of glucocorticoids with side effects can be used for treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of progestational hormone in treatment of cytokine release syndrome
  • Application of progestational hormone in treatment of cytokine release syndrome
  • Application of progestational hormone in treatment of cytokine release syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1 Hydroxyprogesterone Caproate (HPC) Inhibits Cytokine Release in Human Peripheral Blood Mononuclear Cells (PBMCs)

[0026] 1) T cell inflammation suppression experimental method using anti-CD28 superagonist

[0027] first day

[0028] The anti-CD28 superagonist (clone ANC28.1 / 5D10, 2 μg / well) dissolved in PBS 1x was inoculated in a high-binding microtiter plate, incubated overnight in a biological safety cabinet with the cover open, fixed and air-dried. Frozen PBMCs were thawed, mixed and diluted to an appropriate density, inoculated into a U-shaped bottom polypropylene 96-well plate (1.2x105 cells per well), and 228 μL of medium (RPMI 1640, 10% heat-inactivated embryo bovine serum, 1% penicillin / streptomycin, 2mM L-glutamine). Cells were incubated at 37°C, 5% CO2 for 1 hour before adding HPC. HPC was dissolved in 50% ethanol & PBS and further diluted with 20X cell culture medium. Add HPC to PBMCs, repeat three groups in parallel, each group 12 μL (1X), 37 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of hydroxyprogesterone hexanoate in preparation of a drug for inhibiting cytokine storm, especially PBMC cytokine release caused by a CD28 antibody and / or a CD3 antibody. Experimental results show that hydroxyprogesterone hexanoate can inhibit release of multiple PBMC cytokines caused by the CD28 antibody and / or the CD3 antibody in a concentration-dependent manner, and is a potential drug for treating cytokine storm.

Description

technical field [0001] The invention belongs to the field of treatment of immune diseases and infectious diseases. Specifically, the application provides the application of hydroxyprogesterone caproate in the preparation of drugs for inhibiting cytokine storm, especially the release of PBMC cytokines. Background technique [0002] Cytokine release syndrome (CRS) refers to a group of clinical syndromes caused by lymphocyte activation, dissolution and release of a large amount of cytokines after the body is infected or treated with monoclonal antibodies and cytokines. . This phenomenon was first discovered in the early 1990s when the anti-graft rejection drug Moromona-CD3 monoclonal antibody (OKT3) was used. In March 2006, in the British phase I clinical trial of the monoclonal antibody TGN1412, 6 healthy men in the test group experienced multi-organ failure, and 2 of them experienced deep coma, which was later confirmed to be related to the induction of CRS in the body. Thi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/57A61K39/395A61P31/00A61P37/06
CPCA61P31/00A61K39/395A61P37/06A61K31/57
Inventor 胡涛杜涛杜新
Owner SHENZHEN EVERGREEN THERAPEUTICS CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap